ASO Author Reflections: When a New Standard Becomes the Standard: Translating Neoadjuvant Chemo-Immunotherapy for Resectable NSCLC Into Real-World Practice
Jiri Vachtenheim Jr, Fernando Casas-Mendez, Rene Novysedlak, Janis Tavandzis, Boris Sepesi, Robert Lischke · 2026
Read ASO Author Reflections: When a New Standard Becomes the Standard: Translating Neoadjuvant Chemo-Immunotherapy for Resectable NSCLC Into Real-World Practice by Jiri Vachtenheim Jr, Fernando Casas-Mendez, Rene Novysedlak, Janis Tavandzis, Boris Sepesi, Robert Lischke (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13675147.txt.
Description
Jiri Vachtenheim Jr and co-authors reflect in a 2026 article on a new lung cancer care path that is hard to roll out. For decades, surgery came first for fit patients with lung cancer that can be cut out. Drugs that free the immune system changed that order, with strong trial results.
A key 2023 trial showed that immune drugs plus chemo before surgery beat chemo alone on time without events and on full tumor wipe out. The mix soon became the new standard for picked patients. Yet putting it to work varies a lot by health system. It needs skilled teams from many fields, tight planning, and firm support inside each hospital. The authors share lessons on making the standard real in daily care.
Catalog record
| CREATOR | Jiri Vachtenheim Jr, Fernando Casas-Mendez, Rene Novysedlak, Janis Tavandzis, Boris Sepesi, Robert Lischke |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 5 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |